Mereo Historical Financial Ratios
| MREO Stock | USD 3.73 0.04 1.06% |
Mereo BioPharma is lately reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 129 will help investors to properly organize and evaluate Mereo BioPharma Group financial condition quickly.
Mereo |
About Mereo Financial Ratios Analysis
Mereo BioPharma GroupFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Mereo BioPharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Mereo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Mereo BioPharma history.
Mereo BioPharma Financial Ratios Chart
Add Fundamental
Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Mereo BioPharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Mereo BioPharma Group current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Mereo BioPharma's Current Ratio is very stable compared to the past year. As of the 30th of December 2024, Debt To Equity is likely to grow to 0.11, while Price To Sales Ratio is likely to drop 135.14.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 0.3 | 0.36 | 0.28 | 0.26 | Receivables Turnover | 25.7 | 0.55 | 2.68 | 2.55 |
Mereo BioPharma fundamentals Correlations
Click cells to compare fundamentals
Mereo BioPharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mereo BioPharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 7.28 | (80.76) | 9.6 | 7.31 | 30.14 | 31.65 | |
| Book Value Per Share | 0.45 | (0.0443) | 0.17 | 0.1 | 0.0766 | 0.0728 | |
| Free Cash Flow Yield | (0.16) | (0.0235) | (0.006837) | (0.0858) | (0.0141) | (0.0149) | |
| Operating Cash Flow Per Share | (0.51) | (0.0839) | (0.009926) | (0.0644) | (0.032) | (0.0336) | |
| Capex To Depreciation | 0.0133 | 0.01 | 0.83 | 0.0138 | 0.39 | 0.38 | |
| Pb Ratio | 7.28 | (80.76) | 9.6 | 7.31 | 30.14 | 31.65 | |
| Free Cash Flow Per Share | (0.51) | (0.084) | (0.0109) | (0.0644) | (0.0327) | (0.0343) | |
| Roic | (0.54) | (31.54) | (0.21) | (0.57) | (0.51) | (0.53) | |
| Inventory Turnover | (1.97) | (3.52) | (9.84) | (0.35) | (0.32) | (0.33) | |
| Net Income Per Share | (0.39) | (0.48) | 0.0241 | (0.0567) | (0.0447) | (0.0469) | |
| Days Of Inventory On Hand | (185.17) | (103.56) | (37.1) | (1.0K) | (1.2K) | (1.1K) | |
| Payables Turnover | 4.01 | 5.57 | 7.84 | 0.27 | 1.1 | 1.04 | |
| Cash Per Share | 0.39 | 0.19 | 0.0711 | 0.18 | 0.0871 | 0.0827 | |
| Pocfratio | (6.38) | (42.66) | (161.2) | (11.65) | (72.09) | (75.69) | |
| Interest Coverage | (11.3) | (5.89) | (5.23) | (12.96) | (9.86) | (10.36) | |
| Capex To Operating Cash Flow | (4.57E-4) | (5.65E-4) | (0.1) | (2.58E-4) | (0.0198) | (0.0208) | |
| Pfcf Ratio | (6.38) | (42.64) | (146.26) | (11.65) | (70.69) | (74.22) | |
| Days Payables Outstanding | 90.92 | 65.56 | 46.57 | 1.4K | 332.67 | 203.31 | |
| Income Quality | 1.12 | 0.17 | (0.37) | 1.08 | 0.72 | 0.66 | |
| Roe | (0.98) | (0.87) | 10.93 | 0.14 | (0.55) | (0.58) | |
| Ev To Operating Cash Flow | (6.73) | (42.46) | (146.4) | (10.53) | (69.65) | (73.13) | |
| Pe Ratio | (8.41) | (7.39) | 66.37 | (13.23) | (51.7) | (49.11) | |
| Return On Tangible Assets | (0.92) | (0.83) | (5.23) | 0.12 | (0.53) | (0.45) | |
| Ev To Free Cash Flow | (6.73) | (42.44) | (132.83) | (10.53) | (68.3) | (71.71) | |
| Earnings Yield | (0.12) | (0.14) | 0.0151 | (0.0756) | (0.0193) | (0.0203) | |
| Intangibles To Total Assets | 0.51 | 0.5 | 0.19 | 0.27 | 0.0164 | 0.0156 | |
| Net Debt To E B I T D A | (0.43) | 0.15 | 15.5 | 1.04 | 1.98 | 2.03 | |
| Current Ratio | 1.02 | 3.47 | 7.92 | 2.52 | 6.72 | 9.55 | |
| Tangible Book Value Per Share | (0.047) | (0.14) | 0.12 | 0.0626 | 0.075 | 0.0712 | |
| Graham Number | 1.99 | 0.7 | 0.3 | 0.36 | 0.28 | 0.26 | |
| Shareholders Equity Per Share | 0.45 | (0.0443) | 0.17 | 0.1 | 0.0766 | 0.0728 | |
| Debt To Equity | 0.66 | 0.55 | (1.08) | 0.18 | 0.0869 | 0.11 |
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Mereo Stock
Moving against Mereo Stock
| 0.82 | VCEL | Vericel Corp Ord | PairCorr |
| 0.76 | VCYT | Veracyte | PairCorr |
| 0.7 | DRTS | Alpha Tau Medical | PairCorr |
| 0.57 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.56 | SABSW | SAB Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.